| 2024-10-29 |
DBPR116, a prodrug of BPRMU191, in combination with naltrexone as a safer opioid analgesic than morphine via peripheral administration |
Journal of Medicinal Chemistry. 2024 Oct 29;Article in Press. |
 |
| 2024-07-17 |
Discovery of a mu-opioid receptor modulator that in combination with morphinan antagonists induces analgesia |
Cell Chemical Biology. 2024 Jul 17;Article in Press. |
|
| 2022-12-05 |
Benzo[b]thiophene-2-carboxamides as novel opioid receptor agonists with potent analgesic effect and reduced constipation |
European Journal of Medicinal Chemistry. 2022 Dec 5;243:Article number 114728. |
|
| 2022-11 |
Selective and antagonist-dependent µ-opioid receptor activation by the combination of 2-{[2-(6-chloro-3,4-dihydro-1(2H)-quinolinyl)-2-oxoethyl]sulfanyl}-5-phenyl-4,6-(1H,5H)-pyrimidinedione and naloxone/naltrexone |
Bioorganic Chemistry. 2022 Nov;128:Article number 105905. |
|
| 2022-02-05 |
Discovery and development of a novel N-(3-bromophenyl)-{[(phenylcarbamoyl)amino]methyl}-N-hydroxythiophene-2-carboximidamide indoleamine 2,3-dioxygenase inhibitor using knowledge-based drug design |
European Journal of Medicinal Chemistry. 2022 Feb 5;229:Article number 114043. |
|
| 2021-10-14 |
Discovery of BPR1R024, an orally active and selective CSF1R inhibitor that exhibits antitumor and immunomodulatory activity in a murine colon tumor model |
Journal of Medicinal Chemistry. 2021 Oct 14;64(19):14477-14497. |
|
| 2021-05-19 |
Discovery and synthesis of a pyrimidine-based aurora kinase inhibitor to reduce levels of MYC oncoproteins |
Journal of Medicinal Chemistry. 2021 May 19;64(11):7312-7330. |
|
| 2021-01 |
BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapy |
Translational Oncology. 2021 Jan;14(1):Article number 100897. |
|
| 2020-10-08 |
Comparative study between deep learning and QSAR classifications for TNBC inhibitors and novel GPCR agonist discovery |
Scientific Reports. 2020 Oct 8;10:Article number 16771. |
|
| 2020-08 |
BPR6K609: An Aurora kinase inhibitor targeting small cell lung cancer with MYC amplification |
Cancer Research. 2020 Aug;80(16):1937. |
|
| 2020-04 |
BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, produces potent antinociceptive effects with safer properties than morphine |
Neuropharmacology. 2020 Apr;166:Article number 107678. |
|
| 2020-02-10 |
Unique sulfur-aromatic interactions contribute to the binding of potent imidazothiazole indoleamine 2,3-Dioxygenase inhibitors |
Journal of Medicinal Chemistry. 2020 Feb 10;63(4):1642-1659. |
|
| 2019-12 |
Identification of a multitargeted tyrosine kinase inhibitor for the treatment of gastrointestinal stromal tumors and acute myeloid leukemia |
Journal of Medicinal Chemistry. 2019 Dec;62(24):11135-11150. |
|
| 2019-10 |
Inhibition of Rspo-Wnt pathway facilitates checkpoint blockade therapy by anti-RSPO3 antibody (DBPR117) |
Annals of Oncology. 2019 Oct;30(Suppl. 5):191. |
|
| 2019-07-11 |
Linker optimization and therapeutic evaluation of phosphatidylserine-targeting zinc dipicolylamine-based drug conjugates |
Journal of Medicinal Chemistry. 2019 Jul 11;62(13):6047-6062. |
|
| 2019-07 |
Use of integrated genomic analyses in patient-derived tumor model to discover new clinical indications for the multikinase inhibitor drug candidate, DBPR216 |
Cancer Research. 2019 Jul;79(13, Suppl.):Abstract number 4626. |
|
| 2019-07 |
BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapy |
Cancer Research. 2019 Jul;79(13, Suppl.):Abstract number 227. |
|
| 2019-07 |
An Aurora kinase inhibitor BPR6K471 inhibits tumor growth and reduces the cancer stem cell-like properties of small cell lung cancer |
Cancer Research. 2019 Jul;79(13, Suppl.):Abstract number 3851. |
|
| 2019-04-01 |
The in vivo antinociceptive and mu-opioid receptor activating effects of the combination of N-phenyl-2′,4′-dimethyl-4,5′-bi-1,3-thiazol-2-amines and naloxone |
European Journal of Medicinal Chemistry. 2019 Apr 1;167:312-323. |
|
| 2018-12 |
Targeting RSPO3 reduces stem cell function in RSPO3-Fusion-positive colon cancer and RSPO3 high lung cancer |
Cancer Science. 2018 Dec;109(SI, Suppl. 2):210. |
|
| 2018-12 |
Targeting RSPO3 reduces stem cell function in RSPO3-Fusion-positive colon cancer and RSPO3 high lung cancer |
Cancer Science. 2018 Dec;109(Suppl. 2, SI):1257. |
|
| 2018-05-10 |
Design and synthesis of BPR1K653 derivatives targeting the back pocket of Aurora kinases for selective isoform inhibition |
European Journal of Medicinal Chemistry. 2018 May 10;151:533-545. |
|
| 2018-04 |
4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy |
Bioorganic Chemistry. 2018 Apr;77:600-607. |
|
| 2017-07 |
Design, synthesis, and evaluation of thiazolidine-2,4-dione derivatives as a novel class of glutaminase inhibitors |
Journal of Medicinal Chemistry. 2017 Jul;60(13):5599-5612. |
|
| 2017-06-22 |
Targeting coronaviral replication and cellular JAK2 mediated dominant NF-kappaB activation for comprehensive and ultimate inhibition of coronaviral activity |
Scientific Reports. 2017 Jun 22;7:Article number 4105. |
|
